Earnings and Growth Analysis : Clovis Oncology (NASDAQ:CLVS)

0
37

Earnings results for Clovis Oncology (NASDAQ:CLVS)

Clovis Oncology, Inc. is expected* to report earnings on 02/23/2021 before market open. The report will be for the fiscal Quarter ending Dec 2020. According to Zacks Investment Research, based on 5 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.76. The reported EPS for the same quarter last year was $-1.81.

Analyst Opinion on Clovis Oncology (NASDAQ:CLVS)

6 Wall Street analysts have issued ratings and price targets for Clovis Oncology in the last 12 months. Their average twelve-month price target is $9.20, predicting that the stock has a possible upside of 38.35%. The high price target for CLVS is $17.00 and the low price target for CLVS is $3.00. There are currently 2 sell ratings, 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of “Hold.”

Clovis Oncology has received a consensus rating of Hold. The company’s average rating score is 2.00, and is based on 2 buy ratings, 2 hold ratings, and 2 sell ratings. According to analysts’ consensus price target of $9.20, Clovis Oncology has a forecasted upside of 38.3% from its current price of $6.65. Clovis Oncology has only been the subject of 1 research reports in the past 90 days.

Dividend Strength: Clovis Oncology (NASDAQ:CLVS)

Clovis Oncology does not currently pay a dividend. Clovis Oncology does not have a long track record of dividend growth.

Insiders buying/selling: Clovis Oncology (NASDAQ:CLVS)

In the past three months, Clovis Oncology insiders have sold more of their company’s stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $88,510.00 in company stock. Only 6.60% of the stock of Clovis Oncology is held by insiders. 57.83% of the stock of Clovis Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Earnings and Valuation of Clovis Oncology (NASDAQ:CLVS

Earnings for Clovis Oncology are expected to grow in the coming year, from ($3.93) to ($2.38) per share. The P/E ratio of Clovis Oncology is -1.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Clovis Oncology is -1.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

More latest stories: here